Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNYSE:CATXNASDAQ:EMBCNASDAQ:IRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$10.25+1.0%$12.39$7.09▼$21.00$462.27M1.05482,479 shs418,996 shsCATXPerspective Therapeutics$3.81-0.3%$2.75$1.60▼$16.55$282.81M1.091.09 million shs1.38 million shsEMBCEmbecta$9.93-2.8%$11.11$9.49▼$21.48$597.28M1.13489,001 shs366,757 shsIRMDiRadimed$60.40-0.1%$55.21$42.34▼$63.29$769.01M0.9243,668 shs54,387 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+0.99%+10.33%-7.41%-46.02%+40.80%CATXPerspective Therapeutics-0.26%+10.43%+59.41%+65.65%-60.10%EMBCEmbecta-2.84%+1.95%-7.37%-20.11%-18.67%IRMDiRadimed-0.13%+3.34%+18.22%+13.15%+39.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.73 of 5 stars3.52.00.00.02.62.50.6CATXPerspective Therapeutics3.5987 of 5 stars4.63.00.00.03.12.50.0EMBCEmbecta4.0717 of 5 stars3.21.03.30.00.03.33.8IRMDiRadimed4.6791 of 5 stars2.52.02.54.43.23.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$22.20116.59% UpsideCATXPerspective Therapeutics 3.18Buy$12.56229.54% UpsideEMBCEmbecta 2.33Hold$19.3394.70% UpsideIRMDiRadimed 3.00Buy$72.0019.21% UpsideCurrent Analyst Ratings BreakdownLatest CATX, AXGN, EMBC, and IRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.005/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/7/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $10.00(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M2.49N/AN/A$2.36 per share4.34CATXPerspective Therapeutics$1.43M197.77N/AN/A$2.67 per share1.43EMBCEmbecta$1.12B0.52$3.25 per share3.06($12.80) per share-0.78IRMDiRadimed$73.24M10.49$1.58 per share38.22$6.85 per share8.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.15N/AN/AN/A-3.68%-7.09%-3.67%8/6/2025 (Estimated)CATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)EMBCEmbecta$78.30M$0.9011.033.230.654.89%-19.67%12.27%8/8/2025 (Estimated)IRMDiRadimed$19.23M$1.5538.9730.20N/A26.33%23.28%20.59%7/30/2025 (Estimated)Latest CATX, AXGN, EMBC, and IRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/AEMBCEmbecta$0.606.04%N/A66.67%N/AIRMDiRadimed$0.681.13%N/A43.87%1 YearsLatest CATX, AXGN, EMBC, and IRMD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/20255/5/2025IRMDiRadimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.634.282.65CATXPerspective TherapeuticsN/A9.609.60EMBCEmbectaN/A2.481.83IRMDiRadimedN/A8.877.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%CATXPerspective Therapeutics54.66%EMBCEmbecta93.83%IRMDiRadimed92.34%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%CATXPerspective Therapeutics3.72%EMBCEmbecta0.42%IRMDiRadimed36.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45045.54 million44.28 millionOptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableEMBCEmbecta2,10058.44 million58.20 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableCATX, AXGN, EMBC, and IRMD HeadlinesRecent News About These CompaniesiRadimed Corporation (NASDAQ:IRMD) Shares Sold by Rhumbline AdvisersJune 22, 2025 | marketbeat.comProsperity Wealth Management Inc. Acquires Shares of 6,595 iRadimed Corporation (NASDAQ:IRMD)June 18, 2025 | marketbeat.comNew Strong Sell Stocks for June 12thJune 12, 2025 | zacks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 8,774 Shares of Iradimed Corporation (NASDAQ:IRMD)June 11, 2025 | marketbeat.comTwo Sigma Investments LP Sells 21,924 Shares of Iradimed Corporation (NASDAQ:IRMD)June 6, 2025 | marketbeat.comAre Investors Undervaluing IRADIMED CORPORATION (NASDAQ:IRMD) By 34%?June 2, 2025 | finance.yahoo.comSquarepoint Ops LLC Has $867,000 Stock Holdings in Iradimed Corporation (NASDAQ:IRMD)June 2, 2025 | marketbeat.comMillennium Management LLC Cuts Stock Position in Iradimed Corporation (NASDAQ:IRMD)June 2, 2025 | marketbeat.comKings Path Partners LLC Has $649,000 Holdings in Iradimed Corporation (NASDAQ:IRMD)May 31, 2025 | marketbeat.comIradimed (NASDAQ:IRMD) Stock Price Up 8% - Here's What HappenedMay 30, 2025 | marketbeat.comTwo Sigma Advisers LP Has $2.04 Million Holdings in Iradimed Corporation (NASDAQ:IRMD)May 30, 2025 | marketbeat.comIradimed Corporation Announces FDA Clearance for Next-Generation MRidium® 3870 IV Infusion Pump SystemMay 29, 2025 | quiverquant.comQIRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump SystemMay 29, 2025 | globenewswire.comIradimed Corporation (NASDAQ:IRMD) Shares Sold by Man Group plcMay 29, 2025 | marketbeat.comIRADIMED CORPORATION (NASDAQ:IRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$71.00May 9, 2025 | finance.yahoo.comIradimed Corp Bottom Line Rises In Q1May 6, 2025 | nasdaq.comIRadimed Corporation (NASDAQ:IRMD) Q1 2025 Earnings Call TranscriptMay 6, 2025 | msn.comIradimed Announces Quarterly ResultsMay 5, 2025 | baystreet.caIradimed stock surges as Q1 earnings top estimatesMay 5, 2025 | investing.comIRADIMED CORPORATION (IRMD) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comIRadimed (IRMD) Lags Q1 Earnings EstimatesMay 5, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCATX, AXGN, EMBC, and IRMD Company DescriptionsAxoGen NASDAQ:AXGN$10.25 +0.10 (+0.99%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$10.42 +0.16 (+1.61%) As of 06/25/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Perspective Therapeutics NYSE:CATX$3.81 -0.01 (-0.26%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$3.84 +0.03 (+0.81%) As of 06/25/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Embecta NASDAQ:EMBC$9.93 -0.29 (-2.84%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$9.99 +0.06 (+0.64%) As of 06/25/2025 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.iRadimed NASDAQ:IRMD$60.40 -0.08 (-0.13%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$60.31 -0.09 (-0.15%) As of 06/25/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
